NCT06369935Not yet recruiting
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
Source: ClinicalTrials.gov · Last updated 17 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 260 (estimated)
- First submitted
- 11 Apr 2024
- Start date
- 20 Jun 2024
- Primary completion date
- 20 Aug 2026
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT06369935
What you commit to
- Study type: Observational
- Planned participants: 260
- From 20 Jun 2024 to the primary completion date, 20 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Patients who are hypersensitive to the active ingredients of the product or any excipients (dimethyl sulfoxide, compound electrolyte injection, human albumin);
Other
- The researcher believes that patients are unable to return for follow-up visits or that it is impossible to complete the study;
- Patients with expected survival less than 3 months
Who the study is looking for
- Adult patients with confirmed relapsed/refractory multiple myeloma;
- Based on clinical practice, the physician decided to administer equecabtagene autoleucel treatment;
- Voluntarily sign the informed consent form approved by the ethics committee.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.